Approval and access are different things entirely.
Em um momento em que o Brasil ainda busca equilibrar vacinação em massa com o tratamento de casos individuais, a Anvisa autorizou o uso emergencial do Paxlovid, antiviral oral da Pfizer capaz de reduzir em 89% as hospitalizações e mortes por COVID-19 em pacientes de alto risco. A aprovação, concedida após seis semanas de análise técnica, coloca o país em alinhamento com reguladores dos Estados Unidos, Europa e outros países, mas levanta uma questão que transcende a ciência: garantir que um medicamento aprovado chegue, de fato, às mãos de quem precisa.
- Com 89% de redução em hospitalizações e mortes nos ensaios clínicos, o Paxlovid chega como uma das ferramentas antivirais mais promissoras da pandemia — mas sua aprovação não garante acesso imediato à população.
- O medicamento enfrenta um labirinto de restrições: proibido para grávidas, pacientes com insuficiência renal grave, casos severos e uso preventivo, além de ser limitado a apenas cinco dias de tratamento.
- A Anvisa fez questão de reforçar que o antiviral não substitui a vacina, sinalizando o risco de que aprovações de tratamentos enfraqueçam o compromisso público com a imunização.
- O Brasil já acumula um arsenal de medicamentos aprovados — Evusheld, Regdanvimabe, Baricitinibe, Remdesivir — mas vários deles esbarram em falta de estoque ou barreiras de incorporação ao SUS.
- A aprovação abre o caminho regulatório, mas a verdadeira batalha — distribuição, financiamento e incorporação ao sistema público de saúde — ainda está por ser travada.
A Anvisa autorizou na quarta-feira o uso emergencial do Paxlovid, medicamento oral da Pfizer que combina nirmatrelvir e ritonavir no tratamento da COVID-19. A decisão veio após seis semanas de análise por uma equipe multidisciplinar do órgão regulador, que examinou o pedido apresentado pela empresa em 16 de fevereiro. Dados clínicos indicam que o tratamento reduz em 89% as hospitalizações e mortes entre pacientes adultos com risco de progressão para doença grave — um resultado que já havia chamado a atenção de reguladores em todo o mundo.
O medicamento é indicado para adultos que ainda não necessitam de oxigênio suplementar, mas que apresentam risco real de agravamento. Vem, no entanto, cercado de restrições importantes: não pode ser usado em casos severos ou críticos, nem como profilaxia pré ou pós-exposição. O tratamento dura cinco dias. Gestantes estão excluídas, e a agência recomenda evitar gravidez durante o uso e por uma semana após o término. Pacientes com insuficiência renal grave também não devem utilizá-lo. A Anvisa determinou ainda que farmacêuticos orientem cada paciente sobre dosagem, efeitos colaterais e o caráter intransferível da prescrição.
A diretora Meiruze Freitas destacou que a aprovação foi criteriosa e reafirmou que a vacinação continua sendo a principal estratégia de prevenção — um recado deliberado em meio ao avanço da campanha de imunização. O Paxlovid já havia sido aprovado nos Estados Unidos, Europa, Canadá, China, Austrália, Japão e México, e o Brasil seguiu esse consenso internacional com revisão própria.
O país já conta com outros tratamentos autorizados, como o Evusheld, sem estoque disponível, o Regdanvimabe, com fornecimento doméstico, e o Baricitinibe, em processo de incorporação ao SUS. O Remdesivir foi aprovado, mas não recomendado para financiamento público por benefício marginal e custo elevado. A aprovação do Paxlovid representa um avanço regulatório significativo — mas a questão de como o medicamento chegará aos pacientes que dele precisam, especialmente pelo sistema público de saúde, permanece em aberto.
Brazil's health regulator gave the green light on Wednesday to an oral antiviral treatment for COVID-19 that had been waiting in the approval queue since mid-February. The Anvisa, the country's drug and medical device authority, authorized emergency use of Paxlovid, Pfizer's two-part medication combining nirmatrelvir and ritonavir, marking another tool in the Brazilian arsenal against the pandemic.
The drug is meant for adults who are not yet sick enough to need supplemental oxygen but face a genuine risk of their illness turning severe. Company data presented to regulators showed the treatment cut hospitalizations and deaths by 89 percent in clinical trials—a substantial reduction that caught the attention of health authorities worldwide. Pfizer had submitted its request for emergency authorization to Anvisa on February 16, and the agency's multidisciplinary review team spent six weeks examining the evidence before rendering their decision.
Meiruze Freitas, the Anvisa director overseeing the review, emphasized that the approval process had been thorough and that Brazil's regulatory team had worked to ensure citizens could access a range of vaccines and treatments. She was careful to note, however, that Paxlovid is not a substitute for vaccination. The vaccine remains the most effective strategy for preventing infection, hospitalization, and death—a point the agency wanted to underscore as the country continued its immunization campaign.
The medication comes with significant restrictions. It cannot be used in patients with severe or critical COVID-19, nor can it serve as preventive treatment before or after exposure. Treatment is limited to five days. Patients with serious kidney problems should not take it. Pregnant women are excluded entirely, and the agency recommends avoiding pregnancy during treatment and for a week afterward. These guardrails reflect the agency's caution about deploying a new drug in a population still learning its full safety profile.
Pharmacists will be required to counsel every patient on dosage, how to take the medication, and potential side effects. The agency also mandated that pharmacists explain to patients that the treatment is personal and non-transferable—it belongs to the individual who saw a doctor, received a prescription, and was deemed eligible. This emphasis on individual medical oversight reflects a broader principle: no one-size-fits-all approach to COVID treatment.
Paxlovid had already won approval from regulators in the United States and Europe and was in use across Canada, China, Australia, Japan, and Mexico. The U.S. Food and Drug Administration had recommended it for people 12 and older weighing at least 40 kilograms who had mild disease but faced risk of progression to severe illness. Brazil's approval aligned with that international consensus, though the country's regulatory team conducted its own independent review.
The Anvisa decision arrived as Brazil was navigating a crowded landscape of COVID treatments. The agency had already approved several other options: Evusheld, an AstraZeneca monoclonal antibody cocktail authorized in February but with no stock in the country; Regdanvimabe, a Celltrion Healthcare monoclonal antibody with domestic supply; and Baricitinibe, an Eli Lilly drug that had received a favorable preliminary opinion and was moving toward public health system incorporation. Remdesivir, Gilead's injectable antiviral, had been approved but faced a recommendation against public funding due to marginal benefit and high cost. Two other monoclonal antibodies—Sotrovimabe and Regn-Cov2—had been approved but not incorporated into public care.
The real test now lay ahead: whether Paxlovid would actually reach patients who needed it. Approval is one step; availability and affordability are another. The agency had cleared the path. The question of how Brazil would distribute and pay for the drug remained open.
Notable Quotes
The vaccine remains the best strategy for preventing COVID-19, hospitalizations, and deaths— Meiruze Freitas, Anvisa director
The Hearth Conversation Another angle on the story
Why did it take Pfizer six weeks to get approval after submitting in February? Was there something about the drug that required extra scrutiny?
The Anvisa wanted to be thorough. They had a multidisciplinary team review all the evidence—efficacy data, safety signals, contraindications. Six weeks for a new antiviral during a pandemic isn't slow by regulatory standards. They were being careful, not cautious to the point of paralysis.
The 89 percent reduction in hospitalizations and deaths—that's a significant number. Does that mean it works for almost everyone who takes it?
No. That's the reduction in the trial population, which was people at high risk but not yet severely ill. It doesn't mean 89 out of 100 people won't get worse. It means the drug cut the rate of severe outcomes by that proportion compared to placebo. And it only works in that narrow window—early illness, high-risk patients, before oxygen is needed.
Why all the restrictions? Five days maximum, no pregnant women, no kidney disease patients. That seems to eliminate a lot of people.
Those are the populations where either the drug hasn't been tested adequately or where the risks outweigh the benefits. Pregnancy is always cautious territory with new drugs. Kidney disease means the body can't clear the medication properly. Five days is what the trials showed worked. You don't extend a treatment just because you have more of it.
The agency mentions that vaccination is still the best strategy. Does that mean Paxlovid is a backup plan?
Exactly. Paxlovid is for people who got infected despite vaccination, or who couldn't be vaccinated, and are now at risk of getting very sick. It's a safety net, not a replacement for prevention. The Anvisa wanted to be clear about that hierarchy.
I noticed several other COVID drugs were approved but not incorporated into the public health system. Will Paxlovid face the same problem?
That's the open question. Approval and access are different things. The agency cleared it; now the Ministry of Health and the public system have to decide if they'll buy it, at what price, and for whom. That's where the real negotiation begins.